骨髓内残留的正常血细胞在多发性骨髓瘤的各种疾病阶段的临床影响
Wenqiang Yan1,2, Lihui Shi1,2, Jingyu Xu1,2
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
Leukemia
|August 2, 2024
概括
在多发性骨髓瘤患者中,高水平的正常血细胞 (NPC) 表明疾病的侵袭性较小,生存率更高. 监测NPC为风险分层和理解最小残留疾病 (MRD) 提供了宝贵的见解.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 剩余的正常血细胞 (NPC) 与髓瘤细胞竞争,影响疾病的发展.
- 对残留NPC的大规模研究,特别是在最小残留疾病 (MRD) 监测期间,是有限的.
研究的目的:
- 在多发性骨髓瘤疾病过程中调查残留NPCs的临床意义.
- 评估NPC作为风险分层和MRD评估的生物标志物.
主要方法:
- 对来自NICHE队列的1363名多发性骨髓瘤患者的分析 (NCT04645199).
- 评估基线,复发和纵向NPC比率与临床特征和生存结果的关系.
- 基于NPC比率趋势的动态MRD模型的开发.
主要成果:
- 基线高的NPC比率 (≥5%) 与惰的特征相关:较低的瘤负担,减少的细胞减小,较少的免疫衰竭和较少的高风险细胞遗传学.
- 诊断时或复发时高的NPC比率独立地与有利的生存率相关.
- 在无法检测的MRD中,高绝对NPC百分比预测了优越的临床益处和免疫复合.
- NPC比率分组 (<50%,50-90%,≥90%) 在MRD阳性阶段提供了比瘤日志水平更好的风险分层.
- 基于NPC比率趋势的动态MRD模型确定了不同的预后组.
结论:
- 剩余NPC是多发性骨髓瘤风险分层的有价值的补充生物标志物.
- 在MRD监测期间,NPC水平为疾病动力学和重新分类提供了洞察力.
- 监测NPC有助于预测治疗反应和患者预后.
相关概念视频
Bone Marrow Sampling and Transplants
317
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
317
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Disorders of Leukocytes
923
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
923
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K


